SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes.

What was studied

This review pooled studies of SGLT2 inhibitor drugs after aortic valve intervention for aortic stenosis. It compared their use with usual care or no use. It included 11 observational studies and one randomized trial. Most data came from TAVR groups. The search ran through June 2026.

What they found

SGLT2 inhibitor use was linked to lower all-cause mortality. The hazard ratio was 0.69. The study-defined composite outcome was also lower. Its hazard ratio was 0.68. The definitions of its parts differed across studies. Heart failure hospitalization, atrial fibrillation and acute kidney injury showed no significant differences.

What it means for patients

The authors say SGLT2 inhibitor use after valve intervention was linked to lower mortality. They say randomized trials are needed to confirm if this reflects a treatment effect.

Why it is not certain yet

Most data came from observational studies. A link does not prove the drug caused the effect. SAVR data were not similar enough to pool. Results for the composite, heart failure, rhythm, kidney and valve outcomes remain less certain.

Source

SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes.

We restate facts from the source record in our own words. The original wording belongs to its publisher.